Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-27), Bioporto AS's 9-Day RSI is 57.50.
The industry rank for Bioporto AS's 9-Day RSI or its related term are showing as below:
OCSE:BIOPOR's 9-Day RSI is ranked worse than 80.56% of 216
companies
in the Medical Diagnostics & Research industry
Industry Median: 46.565
vs OCSE:BIOPOR: 57.50
Bioporto AS (OCSE:BIOPOR) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Bioporto AS 9-Day RSI Related Terms
OCSE:BIOPOR vs TMO, DHR, IDXX: 9-Day RSI Comparison
For the Diagnostics & Research subindustry, Bioporto AS's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS 9-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Bioporto AS's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (OCSE:BIOPOR) has a 9-Day RSI of 57.50 as of Jul. 27, 2026. According to the industry distribution chart, Bioporto AS ranks #174 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 80.6%.
Is Bioporto AS's 9-Day RSI too high?
Bioporto AS's current 9-Day RSI is 57.50. The Medical Diagnostics & Research industry median 9-Day RSI is 46.57. Bioporto AS's value of 57.50 is 23.5% above this industry median. Based on the distribution chart, Bioporto AS ranks #174 out of 216 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Bioporto AS has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's 9-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #174 out of 216 companies for 9-Day RSI. This places Bioporto AS in the lower half of its industry. The industry median 9-Day RSI is 46.57. Bioporto AS's value of 57.50 is 23.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Diagnostics & Research company?
The median 9-Day RSI among Medical Diagnostics & Research companies is 46.57, based on 216 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current 9-Day RSI of 57.50 is 23.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median 9-Day RSI is 46.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current 9-Day RSI is 57.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Based on GuruFocus' analysis, Bioporto AS (OCSE:BIOPOR) is currently considered Fairly Valued. The stock's GF Value™ is kr1.23, compared to a current price of kr1.18 — trading 4.5% below its estimated fair value. The current 9-Day RSI is 57.50 and 23.5% above the Medical Diagnostics & Research industry median of 46.57. Bioporto AS's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Bioporto AS (OCSE:BIOPOR), the current 9-Day RSI is 57.50 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (OCSE:BIOPOR) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of kr1.18 is trading 4.5% below its estimated GF Value™ of kr1.23.
GuruFocus considers Bioporto AS to be Fairly Valued.
Key valuation signals for OCSE:BIOPOR:
9-Day RSI: 57.50
GF Value™: kr1.23 vs. price of kr1.18 (4.5% below fair value)
Industry Position: 23.5% above the Medical Diagnostics & Research median (#174 of 216)
No single metric tells the full story. See the OCSE:BIOPOR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
72GF Score
Get the complete analysis for OCSE:BIOPOR
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:BIOPOR has been successfully added to your 
